LiSiCA: A Software for Ligand-Based Virtual Screening and Its Application for the Discovery of Butyrylcholinesterase Inhibitors | Journal of Chemical Information and Modeling
![Mechanisms of the Oxidations of NAD(P)H Model Hantzsch 1,4-Dihydropyridines by Nitric Oxide and Its Donor N-Methyl-N-nitrosotoluene-p-sulfonamide | The Journal of Organic Chemistry Mechanisms of the Oxidations of NAD(P)H Model Hantzsch 1,4-Dihydropyridines by Nitric Oxide and Its Donor N-Methyl-N-nitrosotoluene-p-sulfonamide | The Journal of Organic Chemistry](https://pubs.acs.org/cms/10.1021/jo000484h/asset/images/large/jo000484hn00001.jpeg)
Mechanisms of the Oxidations of NAD(P)H Model Hantzsch 1,4-Dihydropyridines by Nitric Oxide and Its Donor N-Methyl-N-nitrosotoluene-p-sulfonamide | The Journal of Organic Chemistry
![Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 - ScienceDirect Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667368122000390-gr4.jpg)
Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 - ScienceDirect
![Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 - ScienceDirect Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667368122000390-gr3.jpg)